Galectin 3 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Pipeline Review, H1 2020’, provides in depth analysis on Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Respiratory, Undisclosed, Genito Urinary System And Sex Hormones, Immunology and Ophthalmology under development targeting Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

– The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects

– The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

G3 Pharmaceuticals Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Glycomantra Inc

GlycoMimetics Inc

Immutics Inc

MandalMed Inc

Proteris Biotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Overview

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Companies Involved in Therapeutics Development

G3 Pharmaceuticals Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Glycomantra Inc

GlycoMimetics Inc

Immutics Inc

MandalMed Inc

Proteris Biotech Inc

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Drug Profiles

belapectin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-0139 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-1211 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-2064 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-200 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMCT-04 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1757 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-03 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-04 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protearin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFD-100 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Dormant Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Discontinued Products

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) – Product Development Milestones

Featured News & Press Releases

Feb 04, 2020: Galectin Therapeutics president and CEO Dr. Harold Shlevin to present at the 3rd Global NASH Congress 2020

Dec 09, 2019: Galectin Therapeutics phase 2 NASH cirrhosis clinical trial results on belapectin (GR-MD-02) published in gastroenterology

Dec 05, 2019: Galectin Therapeutics plans adaptively designed phase 3 NASH-RX clinical trial in NASH Cirrhosis

Nov 11, 2019: Galectin Therapeutics reaches agreement with Siemens Healthineers to collaborate on NASH and Liver Fibrosis

Nov 05, 2019: Additional Ad Hoc analysis of ELF data from Galectin Therapeutics NASH-CX phase 2 clinical trial to be highlighted in poster presentation at the 2019 AASLD Liver Meeting

Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy

Aug 05, 2019: Galectin Therapeutics submits phase 3 NASH-RX protocol in Nash Cirrhosis to FDA

Mar 22, 2019: Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

Dec 04, 2018: GlycoMimetics presents poster at 60th ASH Annual Meeting highlighting preclinical data on GMI-1757

Nov 05, 2018: Data collected by Exalenz Bioscience in Galectin Therapeutics phase 2 NASH-CX trial of GR-MD-02 to be presented at AASLD Annual Meeting

Sep 20, 2018: Galectin Therapeutics announces positive preliminary results from phase 1b clinical trial of GR-MD-02 and KEYTRUDA in advanced melanoma and expansion of the Trial

Jul 18, 2018: GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)

Jun 27, 2018: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

Jun 12, 2018: Galectin Therapeutics Announces New CEO

Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by G3 Pharmaceuticals Inc, H1 2020

Pipeline by Galectin Therapeutics Inc, H1 2020

Pipeline by Galecto Biotech AB, H1 2020

Pipeline by Glycomantra Inc, H1 2020

Pipeline by GlycoMimetics Inc, H1 2020

Pipeline by Immutics Inc, H1 2020

Pipeline by MandalMed Inc, H1 2020

Pipeline by Proteris Biotech Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports